Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
Meta-analysis finds oral SERDs improve PFS over standard ET in HR+ HER2- ABC
New Drug Helps Some Breast Cancer Patients Live Longer
This systematic review and meta-analysis of 2,808 patients with HR+ HER2- advanced breast cancer found oral SERDs improved progression-free …
New oral pills help some advanced breast cancer patients live longer and fight back against drug resistance by blocking estrogen growth sign…
Research across Hormone Receptor-Positive Breast Cancer
Related studies from across the Hormone Receptor-Positive Breast Cancer family.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
Gut bacteria and diet may hold new keys for triple-negative breast cancer care
This narrative review examines the role of gut microbiome composition, antibiotics, obesity, and dietary modulation in triple-negative breas…
A review explores how gut bacteria, antibiotics, and diet could change treatment for triple-negative breast cancer patients.
Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
Docetaxel chemotherapy linked to rare heart attack in breast cancer patient
This case report and literature review examines acute myocardial infarction following docetaxel chemotherapy in a patient with triple-negati…
A rare heart attack occurred after docetaxel chemotherapy in a patient with triple-negative breast cancer. This case review suggests the dru…
Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
A Hidden Protein in Aggressive Breast Cancer May Unlock New Treatments
This meta-analysis of 12 studies in 1,545 TNBC patients found a pooled NY-ESO-1 expression prevalence of 16.1%. The authors note substantial…
A protein found in about one in six triple-negative breast cancers could open the door to immune-based treatments that target cancer cells w…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
Adding immune drugs to chemo helps early stage triple negative breast cancer patients stay disease free longer
A meta-analysis found neoadjuvant immune checkpoint inhibitors with chemotherapy significantly improved event-free survival but not overall …
A large review of trials found that adding immune checkpoint inhibitors to chemotherapy improves survival chances for early stage triple neg…
Radiofrequency ablation followed by radiation therapy shows noninferior 5-year recurrence-free survival compared to partial mastectomy in early stage breast cancer
Radiofrequency Ablation Offers Breast Cancer Patients a Less Invasive Option
This Phase 3 multicenter study evaluated 370 female patients with early stage breast cancer (Tis-T1, N0M0). Radiofrequency ablation followed…
A new five-year study proves that a needle-based treatment works just as well as removing part of the breast for early stage cancer.
Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
New drug combo did not extend life for metastatic triple-negative breast cancer patients in this trial
This phase III RCT in 812 patients with previously untreated metastatic triple-negative breast cancer found that adding capivasertib to pacl…
A large global trial found that adding capivasertib to paclitaxel did not improve overall survival for patients with metastatic triple-negat…